Kornimate/medical-research-clean huggingface dataset:
foot and ankle edema post-cesarean delivery

Conditions: Foot and Ankle Edema

Summary: some women develop swollen feet and ankles after a cesarean delivery. these women will often complain that their shoes are too tight and their feet may become numb or they may have some tingling in their feet. currently we do not know for sure that foot swelling occurs after a cesarean delivery and if it does what the cause is. if we find that feet do swell after a cesarean delivery we may be able to suggest a cause. this may in the future prevent women developing excessive foot swelling. we aim to investigate whether the size and shape of women's ankles do change following an elective cesarean delivery. we plan to investigate, if possible, the cause of any foot swelling after a cesarean whether it be the volume of intra venous fluids or oxytocin use.

pregnant women booked for an elective cesarean delivery will be recruited into the study. their foot volumes, based on volumetry, and foot and ankle circumferences will be measured prior to administration of iv fluids and then at 24 and 48 hours post delivery. they will also be questioned about their feet with regards to swelling, any symptoms of edema, and their mobility in the preceding two hours. total fluid balance for the first 24 hours post delivery will be calculated, using the estimated blood loss in the or, urine output, iv hydration and oral intake. the amount of oxytocin used will also be recorded. the parturient will be asked to fill in a form indicating the amount of oral fluid consumed in the first 24 hours post delivery. information in the anaesthetic technique, height of block, use of vasopressors etc will be collected retrospectively from the anesthetic chart. to reduce the chance of the caregivers altering their practice during the study, the attending anesthesiologist for the elective cesarean delivery will be unaware of the subject's participation in the study so that the iv fluids he or she gives will be as close to real practice as possible. current practice for iv start and infusion in the surgical daycare area will be used during the study period without modification. validation and reproducibility will also be investigated. each investigator will measure the volume and circumference of the same limb 10 times and inter and intra tester reliability will be calculated.

Eligibility criteria:
inclusion criteria: 1. women with a singleton pregnancy; 2. undergoing an elective cd under regional anesthesia (spinal or combined spinal epidural (cse); 3. normotensive; and 4. at least 37 weeks gestation exclusion criteria: 1. reasons for potential excessive blood loss (e.g. placenta previa); 2. reasons for potential uterine atony and above average use of oxytocin (e.g. multiple pregnancies, polyhydramnios); 3. non lower segment uterine incision; 4. renal or cardiac disease; 5. use of diuretics; or 6. open wounds on the right foot and ankle.

Keywords: foot ankle edema
observational study evaluating long-term safety and effectiveness of humira in patients with hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa (HS)

Summary: the objective of this study is to evaluate the long-term safety and effectiveness of humira in patients with hidradenitis suppurativa (hs) in real-world clinical practice in japan.


Eligibility criteria:
inclusion criteria: * participants who have been prescribed humira by their treating physician as per routine clinical practice for the treatment of hs. exclusion criteria: * participants previously treated with humira. * participants who do not provide consent.

Keywords: hidradenitis suppurativa (hs) humira adalimumab
comparison of the different exercises on chronic neck pain

Conditions: Neck Pain; Pain, Neck

Summary: neck pain is a widespread problem in the general population and is second only to low back pain in musculoskeletal issues.

the aim of this study is to compare the conventional therapy, cervical stabilization exercise approach, and core stabilization exercise in addiction to cervical stabilization in patients with chronic neck pain.

Eligibility criteria:
inclusion criteria: * chronic neck pain more than 3 months * medically stable exclusion criteria: * patients with benign or tumors in the cervical region * patients with active, localized osseous and discal infection in the spine (spondylodiscitis) * patients with history of spinal fractures * patients with congenital anomaly * patients with neck surgery and spinal instability
the role of mind body therapy in geriatric rehabilitation

Conditions: Elderly; Treatment

Summary: background: the main goal of geriatric rehabilitation reconditioning following an acute illness is rapid restoration of normal activity. key elements are pain control, restoration of bowel functions, sleep, appetite and general well-being, along side the physical activity. objective: to assess the effect of mind-body intervention as an adjunct to medical and physical rehabilitation in geriatric patients. design: prospective study setting: university affiliated large city general hospital


Eligibility criteria:
inclusion criteria: * suitable candidates had to be aged 18 years or older * treated in the geriatric rehabilitation department in the tel aviv sourasky medical center (tasmc) and * were willing and able to complete the study protocol. exclusion criteria: * severe unstable chronic illness (e.g., congestive heart failure, chronic renal failure, cancer).

Keywords: patients in a sub-acute geriatric rehabilitation department
efficacy of community reinforcement approach (cra) in the treatment of cannabis users

Conditions: Cannabis Dependence

Summary: substance abuse is not a new phenomenon in pakistan. its prevalence is increasing day by day due to multi-factorial reasons including psychological, cultural, biological, environmental, social and personal factors. recent statistics shows an alarming increase in the use of substance. the last survey conducted indicates there are 3.6 million substance users in pakistan and 3.6 percent among them are cannabis users. furthermore, cannabis is found to be the most prevalent abused drug with adverse impact on the mental health among university students in pakistan. however, there is a dearth of literature which could indicate a well-established treatment policy with proven efficacy model available in pakistan. this study aims to investigate the efficacy of community reinforcement approach (cra) as evidence based remedy for cannabis users. the study is designed in a randomized controlled trial (rct) consisting of groups: active treatment (at; with nine sessions of cra intervention) and treatment as usual (tau; routine treatment). after screening and baseline, participants will be assigned to the either active treatment group or treatment as usual group. participants in both groups will be assessed on completion of third month after randomization (outcome assessment), six months after randomization (first follow-up), and finally ninth months after randomization (second follow up). the primary outcome measure will be the frequency of usage, abstinence period and quantity of cannabis by using timeline follow back interview. the duration of the study is two and half years


Eligibility criteria:
inclusion criteria: 1. aged 18-30. 2. current, regular cannabis use, defined as the use of any cannabis product at least twice per week over the course of the past 12 months. 3. participant able to provide informed consent and willing to participate in the study. exclusion criteria: 1. icd-11 dependence (in the previous 12 months) on alcohol or any other illicit drug (apart from cannabis) with symptoms of withdrawal, tolerance or craving. 2. current use of opiate substitution or sedative-hypnotic medication. 3. having been treated for cannabis use problems with any other treatment within the previous three months. 4. participant with lifetime psychotic disorder. 5. participants with moderate, severe and extremely severe scores on (dass-21) will be excluded. severe learning disability or a pervasive developmental disorder. 6. signs of severe non-cannabis-related intoxication.
comparison of the subjective well-being and tolerability of quetiapine xr to risperidone

Conditions: Schizophrenic Disorders

Summary: the trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine xr (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one year. secondary outcome measures have been selected for helping in the differentiation of the compared atypical antipsychotics. the primary objective of this study is to demonstrate the non-inferiority of quetiapine xr to risperidone assessed at month 6 in terms of responder rate using the self-report instrument swn-k


Eligibility criteria:
inclusion criteria: * treated for symptomatic schizophrenia (dsm-iv-tr codes: 295.10, 295.20, 295.30,295.60, 295.90) or schizoaffective disorder (dsm-iv-tr code:295.70) or schizophreniform disorder (dsm-iv-tr code: 295.40). patients with co-morbid depressive symptoms may be enrolled * patient with first episode of the above mentioned disease (item 3) or patient requiring a medication change for clinical reasons (effectiveness, tolerability, compliance, patient preference), i.e. switch from typical to atypical neuroleptics, switch from other atypical neuroleptics, excluding patients treated with risperidone or quetiapine at the time of enrolment. exclusion criteria: * patients with a baseline swn-k total score of \>75 * patients with previous treatment with risperidone or quetiapine may be enrolled if change of treatment has not been dictated by major lack of tolerability and efficacy and if date of last dose has been at least 3 months prior to enrolment.

Keywords: schizophrenia swnk
"self-consciousness and the inter-subjective body"

Conditions: Anorexia Nervosa

Summary: the purpose of this study is to demonstrate that bodily self-consciousness is subjectively and inter-subjectively constituted and that some dimensions of the bodily self-consciousness are impaired in anorexia nervosa.

anorexia nervosa is a severe psychiatric disorder, with high level of mortality. anorexic patients often experience a serious disturbance in body and their own shape perception. we hypothesize that bodily self-consciousness is co-constituted by four subjective dimensions which are all inter-subjectively open: in encountering others, one's body is experienced as 1. objectified, 2. the bearer of inter-subjective feelings, 3. an inter-subjective agent and 4. the anchor of an inter-subjectively negotiated perspective. across several experiments, we sought to determine which dimension of bodily self-consciousness is altered in anorexia nervosa compared to healthy subjects.

Eligibility criteria:
inclusion criteria: * women * from 18 to 35 years old * understanding and being fluent in french * hospitalized or followed in consultation for anorexia nervosa (restrictive anorexia or purge according to the mini) * informed consent signed by the patient * diagnosis of anorexia according to her psychiatrist (and confirmed by the dsm iv) with a bmi between 11 and 18. exclusion criteria: * somatic pathology (cancer, cardiac, renal or respiratory insufficiency, central neurological affection), evolutionary, or risking to be life-threatening within less than year * neurological histories (neurological pathology susceptible to alter attentionnal capacities or field of vision and vision of colors (encephalitis, degenerative brain tumour (méningiome, gliome, astrocytome), congenital neurodegenerative pathology, multiple sclerosis, amyotrophic side hardening, epilepsy) * neuroleptic or psychotropic treatment in doses inferring a slumber, a disorder of the concentration * dyschromatopsie * no insurance * comorbidity of psychiatric type

Keywords: bodily self-consciousness intersubjective body anorexia nervosa joint perception task interoceptive awareness
effect of glucose-insulin-potassium solution on myocardial protection during off-pump coronary bypass surgery in patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: patients undergoing multivessel off-pump coronary bypass surgery (opcab) inevitably experience cumulative ischemia-reperfusion injury at myocardium. glucose-insulin-potassium (gik) is a potentially useful adjunct to myocardial protection. this study was designed to evaluate the effects of gik infusion on myocardium in patients undergoing opcab. patients undergoing opcab with acute coronary syndrome are randomly assigned to gik or control group. the trial is double-blind and conducted at a single center.


Eligibility criteria:
inclusion criteria: * patients undergoing isolated opcab. * age: 20\~75. exclusion criteria: * emergency operation. * patients with mr ≥ 2. * patients with iddm. * patients with random sugar ≥ 250 mg/dl. * patients with serum creatinine ≥ 2.0 mg/dl. * patients with acute myocardial infarction within 1 week of surgery
antioxidant supplementation in pregnant women with low antioxidant status

Conditions: Preeclampsia

Summary: the purpose of this study is to investigate antioxidants supplementation in pregnant women with low antioxidant status at 10-12 weeks gestation age in relation to adverse pregnancy outcome in randomized prospective study.

preeclampsia still remains a leading cause of feto-maternal mortality and morbidity in developed and developing world. despite of intensive research, the underlying pathologic mechanisms of this disease remain elusive. it has been agreed that incomplete or absent transformation of spiral arteries by replacing endothelial cells and mural vascular smooth muscle cells has been observed in the placental bed of preeclamptic patients and severe cases of intrauterine growth restriction. oxidative stress has been proposed as a link between these mechanisms. however, it has been demonstrated by two large studies that antioxidant supplementation does not reduce the risk of preeclampsia. our initial study has been shown that antioxidant supplementation may be reduce the risk of preeclampsia in pregnant women with low antioxidant status. comparison(s): adverse pregnancy outcome between vitamin c and e given and placebo given to pregnant women with low antioxidant status at 10-12 weeks gestation age

Eligibility criteria:
inclusion criteria: * agree to consent form, and consent to protocol of research * known healthy singleton 6-10 weeks pregnant women exclusion criteria: * blood pressure \> 135/85 * proteinuria * history or current use of anti-hypertensive medication or diuretics * use of vitamins c \> 150 mg and/or e \> 75 iu per day * pregestational diabetes * known placental abnormalities. * current pregnancy is a result of in vitro fertilization * regular use of platelet active drugs or non-steroidal anti-inflammatory drugs * known fetal abnormalities * documented uterine bleeding within a week of screening * uterine malformations * history of medical complications * illicit drug or alcohol abuse during current pregnancy * intent to deliver elsewhere * known psychologic problems. * participating in another interventional study

Keywords: antioxidant supplementation preeclampsia prevention
vasomotor symptom alleviation through acupuncture in patients with prostate cancer

Conditions: Prostate Cancer

Summary: a pilot study to assess the acceptability and efficacy of acupuncture in alleviating vasomotor symptoms (hot flushes and night sweats) in irish patients with prostate cancer receiving androgen deprivation therapy.


Eligibility criteria:
inclusion criteria: * all participants must have a histologically confirmed diagnosis of prostate cancer and currently be treated with androgen deprivation therapy with or without additional prostate cancer therapies. * patients under the care of a medical oncologist in either bons secours hospital or cork university hospital * all participants must be experiencing moderate to severe vasomotor symptoms as defined by a score of 4 or more on the hot flash index. exclusion criteria: * patients under 18. * patients with hfi scores below 4. * patients not currently being treated with androgen deprivation therapy. * patients with contraindications to acupuncture. * patients already receiving acupuncture for vasomotor symptoms. * patients unwilling to participate in the study.
ammonia levels and cognitive impairment

Conditions: Dementia; Cognitive Decline; Cognitive Impairment; Developmental Delay

Summary: the purpose and objective of this study is to determine the prevalence of elevated ammonia levels in subjects with cognitive impairment, and to observe if treating the cause of the elevated ammonia level improves mental status. this study does not include any imaging, treatment,or interventions, other than the blood draws. the blood draws will be taken to assess blood ammonia level and liver function. if the the ammonia level is not elevated, no further lab draws will occur. if the ammonia level is elevated, liver function is normal, and a cause for the high ammonia level is revealed with a plan for clinical treatment by the subjects' physician, then two more blood draws will occur; one prior to treatment, and one 3 months after treatment. the main risk to subjects is related to the blood draw (i.e. momentary discomfort, bruising, infection, bleeding, clotting or fainting), and there is a potential loss of confidentiality. a paired student t test will be done with the two later blood to compare objective data.


Eligibility criteria:
inclusion criteria: * cognitive decline (suspected or documented) * able to get blood drawn exclusion criteria: * liver disease/cirrhosis

Keywords: dementia alzheimer's alzheimers cognitive decline cognitive impairment memory loss memory disorder forgetfulness confusion senile demented developmental delay portal systemic shunting high ammonia level elevated ammonia level
study of bmn 110 in pediatric patients < 5 years of age with mucopolysaccharidosis iva (morquio a syndrome)

Conditions: Mucopolysaccharidosis IVA; Morquio A Syndrome; MPS IVA

Summary: this open-label phase 2 study will evaluate the safety and efficacy of weekly 2.0 mg/kg/wk infusions of bmn 110 in pediatric patients, less than 5 years of age at the time of administration of the first dose of study drug, diagnosed with mps iva (morquio a syndrome) for up to 208 weeks.


Eligibility criteria:
inclusion criteria: * less than 5 years of age at the time of the first study drug infusion * documented clinical diagnosis of mps iva based on clinical signs and symptoms of mps iva and documented reduced fibroblast or leukocyte galns enzyme activity or genetic testing confirming diagnosis of mps iva * written informed consent provided by parent or legally authorized representative after the nature of the study has been explained and prior to any research-related procedures. exclusion criteria: * previous hematopoietic stem cell transplant (hsct). * previous treatment with bmn 110. * known hypersensitivity to any of the components of bmn 110. * major surgery within 3 months prior to stuy entry or planned major surgery during the 52-week treatment period. * use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments. * concurrent disease or condition, including but not limited to symptomatic cervical spine instability, clinically significant spinal cord compression, or severe cardiac disease that would interfere with study participation or safety as determined by the investigator. * any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study.

Keywords: mucopolysaccharidosis iva type a mps iva type a mucopolysaccharidosis iva mps iva morquio a syndrome lysosomal storage disorder lsd n-acetylgalactosamine-6-sulfatase n-acetylgalactosamine-6-sulfate sulfatase galactose-6-sulfatase galns enzyme replacement therapy ert
a study of subcutaneous versus intravenous mabthera/rituxan (rituximab) in combination with chop chemotherapy in patients with previously untreated cd20-positive diffuse large b-cell lymphoma

Conditions: Lymphoma, Large B-Cell, Diffuse

Summary: this multicenter, randomized, open label parallel-group study will evaluate the efficacy and safety of subcutaneous versus intravenous mabthera/rituxan (rituximab) in combination with chop chemotherapy in patients with previously untreated cd20-positive diffuse large b-cell lymphoma. patients will be randomized to receive either mabthera/rituxan 1400 mg subcutaneously or mabthera/rituxan 375 mg/m2 intravenously on day 1 of each cycle for 8 cycles, in combination with 6-8 cycles of chop chemotherapy. anticipated time on study treatment is 6 months.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 and \</= 80 years of age at time of study inclusion * histologically confirmed, previously untreated cd20-positive diffuse large b-cell lymphoma (dlbcl) according to the who classification system * patients with an international prognostic index (ipi) score 1-5, or ipi score 0 with bulky disease, defined as one lesion \>/= 7.5 cm * at least one bi-dimensionally measurable lesion defined as \>/= 1.5 cm in its largest dimension on ct scan, pet-ct scan or mri * adequate hematologic function * eastern cooperative oncology group (eocd) performance status \</= 2 exclusion criteria: * primary or secondary central nervous system lymphoma, histologic evidence of transformation to burkitt lymphoma, primary mediastinal dlbcl, primary effusion lymphoma, primary cutaneous dlbcl, or primary dlbcl of the testis * transformed lymphoma or follicular lymphoma iiib * prior therapy for dlbcl, with the exception of nodal biopsy or local irradiation * history of other malignancy, except for curatively treated basal or squamous cell carcinoma or melanoma of the skin, carcinoma in situ of the cervix, or a malignancy that has been treated without curative intent and has been in remission without treatment for \>/= 5 years prior to enrolment * inadequate renal or hepatic function * known human immunodeficiency virus (hiv) infection or hiv seropositive status * active hepatitis b virus (hbv) or active hepatitis c virus (hcv) infection. patients with occult or prior hbv infection as defined by protocol may be included. patients positive for hcv antibody are eligible only if polymerase chain reaction testing for hcv ribonucleic acid is negative. * history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products * contraindication to any of the individual components of chop, including prior receipt of anthracyclines * prior treatment with cytotoxic drugs or rituximab for another condition (e.g. rheumatoid arthritis) or prior use of an anti-cd20 antibody * pregnant or lactating women